FDA approves Arcutis' Zoryve (roflumilast) cream, a steroid-free treatment for mild-moderate atopic dermatitis.
The FDA has approved Arcutis Biotherapeutics' Zoryve (roflumilast) cream, a once-daily, steroid-free treatment for mild to moderate atopic dermatitis in adults and children aged 6 and older. Zoryve provides rapid relief and is effective for up to 56 weeks of treatment, offering a safer and steroid-free alternative to topical and systemic steroids. The drug has demonstrated efficacy, safety, and tolerability in numerous clinical trials and is expected to be widely available by the end of July.
July 09, 2024
13 Articles